PDF) The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
Cardiovascular Medicine - Current trends in dual antiplatelet therapy: a 2017 update
Antiplatelet Drugs in the Management of Coronary Artery Disease - ScienceDirect
Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent - ScienceDirect
Antiplatelet Drugs in the Management of Coronary Artery Disease - ScienceDirect
PCI for STEMI - The Cardiology Advisor
Stent Thrombosis: A Clinical Perspective | JACC: Cardiovascular Interventions
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
PDF) Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX
60145-x.fp.png "INCIDENCE AND PREDICTORS OF STENT THROMBOSIS AFTER PCI IN ACUTE MYOCARDIAL INFARCTION | Journal of the American College of Cardiology")
INCIDENCE AND PREDICTORS OF STENT THROMBOSIS AFTER PCI IN ACUTE MYOCARDIAL INFARCTION | Journal of the American College of Cardiology
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
Angiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study - Généreux - 2017 - Catheterization and Cardiovascular Interventions - Wiley Online Library
Cathlab & Cardiovascular News
The evolution of antiplatelet therapy in cardiovascular disease | Nature Reviews Cardiology
Intra-Procedural Stent Thrombosis: A New Risk Factor for Adverse Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes | JACC: Cardiovascular Interventions
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Bernardo Cortese M.D. - Page 10 of 22 - Interventional Cardiologist
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Cangrelor compared with clopidogrel improves efficiency without incre…
Rapamune (Sirolimus) Market Share, Size 2020 By Industry Future Demand, Global Research, Top Leading Players, Developing Trends, Region Forecast To 2026 | News Break
2014 ESC/EACTS Guidelines on myocardial revascularization – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
